BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26089072)

  • 1. Skin moisturization for xerosis related to targeted anticancer therapies.
    Gisondi P; Girolomoni G
    J Am Acad Dermatol; 2015 Jul; 73(1):e33. PubMed ID: 26089072
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to: "Skin moisturization for xerosis related to targeted anticancer therapies".
    Valentine J; Belum VR; Duran J; Ciccolini K; Schindler K; Wu S; Lacouture ME
    J Am Acad Dermatol; 2015 Jul; 73(1):e35-6. PubMed ID: 26089073
    [No Abstract]   [Full Text] [Related]  

  • 3. Incidence and risk of xerosis with targeted anticancer therapies.
    Valentine J; Belum VR; Duran J; Ciccolini K; Schindler K; Wu S; Lacouture ME
    J Am Acad Dermatol; 2015 Apr; 72(4):656-67. PubMed ID: 25637330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dermatological side effects of current and upcoming targeted therapies in oncology.
    Bonny M; Buyse V; Brochez L
    Acta Clin Belg; 2011; 66(2):97-103. PubMed ID: 21630605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skin adverse events in recently approved targeted therapies in solid malignancies.
    Habre M; Salloum A; Habre SB; Abi Chebl J; Dib R; Kourie HR
    Future Oncol; 2019 Jan; 15(3):331-343. PubMed ID: 30523696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of cutaneous toxicities to EGFR inhibitors.
    Lacouture ME
    Nat Rev Cancer; 2006 Oct; 6(10):803-12. PubMed ID: 16990857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Skin disorders].
    Uhara H
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():450-3. PubMed ID: 25831801
    [No Abstract]   [Full Text] [Related]  

  • 8. Skin care for cancer patients.
    Lacouture ME
    Clin Adv Hematol Oncol; 2012 Nov; 10(11):748-50. PubMed ID: 23271263
    [No Abstract]   [Full Text] [Related]  

  • 9. Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.
    Belum VR; Washington C; Pratilas CA; Sibaud V; Boralevi F; Lacouture ME
    Pediatr Blood Cancer; 2015 May; 62(5):798-806. PubMed ID: 25683226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted agents: management of dermatologic toxicities.
    Burtness B
    J Natl Compr Canc Netw; 2014 May; 12(5 Suppl):793-6. PubMed ID: 24853219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events of targeted therapies.
    Klastersky JA
    Curr Opin Oncol; 2014 Jul; 26(4):395-402. PubMed ID: 24825019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.
    Grávalos C; Sanmartín O; Gúrpide A; España A; Majem M; Suh Oh HJ; Aragón I; Segura S; Beato C; Botella R
    Clin Transl Oncol; 2019 May; 21(5):556-571. PubMed ID: 30284232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Managing cutaneous toxicities of targeted therapies].
    Kiyohara Y
    Gan To Kagaku Ryoho; 2012 Nov; 39(11):1597-602. PubMed ID: 23152009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management and interpretation of novel toxicities of molecular targeted therapies: renal toxicities.
    Carles J; Morales R; Perez JM; Suárez C; Rodón J; Valverde C
    Eur J Cancer; 2009 Sep; 45 Suppl 1():309-17. PubMed ID: 19775627
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis.
    Abdel-Rahman O; ElHalawani H; Fouad M
    Future Oncol; 2015; 11(17):2471-84. PubMed ID: 26274495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer.
    Tang N; Ratner D
    Dermatol Surg; 2016 Jan; 42 Suppl 1():S40-8. PubMed ID: 26730973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New drugs in oncology and skin toxicity].
    Mateus C; Robert C
    Rev Med Interne; 2009 May; 30(5):401-10. PubMed ID: 19299041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathology and management of dermatologic toxicities associated with anti-EGFR therapy.
    Fox LP
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):26-34. PubMed ID: 16736980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted cancer therapies, part 2 #277.
    Gharwan H; Groninger H
    J Palliat Med; 2014 Mar; 17(3):358-60. PubMed ID: 24528156
    [No Abstract]   [Full Text] [Related]  

  • 20. Non-rash skin toxicities associated with novel targeted therapies.
    Lacouture ME; Boerner SA; Lorusso PM
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S36-42. PubMed ID: 17239289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.